During the first half of 2025, the overall batch release of vaccines in the industry dipped to 1,629 batches, marking a 17% year-on-year decrease. Notably, the batch release volumes of rabies and HPV vaccines surged significantly, whereas those of poliomyelitis, meningitis, and measles-mumps-rubella vaccines witnessed notable year-on-year declines. In the realm of research and development, several high-profile vaccine varieties, including CanSino's PCV13 and Wantai Biopharma's 9-valent HPV vaccine, secured marketing approvals in the first six months of the year. Concurrently, multiple products, such as Zhifei Biosciences' PCV15 and MCV4, as well as Contech's IPV and quadrivalent influenza vaccine, are currently under review for marketing approval. It is anticipated that the sales of certain vaccine products will improve on a year-over-year basis in the second half of 2025, with the launch of new products poised to deliver incremental performance contributions.